Action Biomerica - BMRA

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,5725

Prix Achat

0,56

Prix Vente

0,59

Volume échangé

188 806

0,55 Fourchette du Jour 0,617

0,2415 Plage de 52 semaines 1,27

Cap du marché

10,498M

Clôture Veille

0,604

Ouverture

0,60

Dernière Transaction

0.56

Dernière heure de transaction

Volume financier

US$ 108 638

VWAP

0,575397

Volume moyen (3 m)

8 451 352

Actions en circulation

18 336 994

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,78

Bénéfice par action (BPA)

-0,33

Chiffre d'affairess

5,42M

Bénéfice net

-5,98M

Biomerica Inc is engaged in the development, manufacturing, and marketing medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain es... Biomerica Inc is engaged in the development, manufacturing, and marketing medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. Majority of the company's revenue is earned from the Europe market. Show more

Secteur

In Vitro,in Vivo Diagnostics

Industrie

In Vitro,in Vivo Diagnostics

Site Web

www.biomerica.com

Siège social

Wilmington, Delaware, USA

Fondé

Biomerica Inc est coté dans le secteur In Vitro,in Vivo Diagnostics de la NASDAQ avec le ticker BMRA. Le dernier cours de clôture d'Biomerica était de US$0,60. Au cours de la dernière année, les actions de Biomerica ont été négociées dans une fourchette de prix de US$ 0,2415 à US$ 1,27.

Biomerica compte actuellement 18 336 994 actions en circulation. La capitalisation boursière d'Biomerica est de US$11,08 million. Biomerica a un ratio cours/bénéfice (ratio PE) de -1.78.

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring...

Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.1075	-15.8088235294	0.68	0.70499	0.57	193149	0.62412863	CS
4	-0.1235	-17.7442528736	0.696	1.1	0.57	918171	0.83727208	CS
12	0.2731	91.2157648631	0.2994	1.27	0.26	8451352	0.70216322	CS
26	0.2725	90.8333333333	0.3	1.27	0.26	4189282	0.66624212	CS
52	-0.4475	-43.8725490196	1.02	1.27	0.2415	2205107	0.65262463	CS
156	-3.1375	-84.5687331536	3.71	5.25	0.2415	899924	0.89868903	CS
260	-2.2075	-79.4064748201	2.78	23.39	0.2415	832661	3.21223194	CS

BMRA - Frequently Asked Questions (FAQ)

What is the current Biomerica share price?

The current share price of Biomerica is US$ 0,5725

How many Biomerica shares are in issue?

Biomerica has 18 336 994 shares in issue

What is the market cap of Biomerica?

The market capitalisation of Biomerica is USD 11,08M

What is the 1 year trading range for Biomerica share price?

Biomerica has traded in the range of US$ 0,2415 to US$ 1,27 during the past year

What is the PE ratio of Biomerica?

The price to earnings ratio of Biomerica is -1,78

What is the cash to sales ratio of Biomerica?

The cash to sales ratio of Biomerica is 1,96

What is the reporting currency for Biomerica?

Biomerica reports financial results in USD

What is the latest annual turnover for Biomerica?

The latest annual turnover of Biomerica is USD 5,42M

What is the latest annual profit for Biomerica?

The latest annual profit of Biomerica is USD -5,98M

What is the registered address of Biomerica?

The registered address for Biomerica is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Biomerica website address?

The website address for Biomerica is www.biomerica.com

Which industry sector does Biomerica operate in?

Biomerica operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
RGCRegencell Bioscience Holdings Ltd	US$ 14,25 (239,29%)	23,33M
LZMHLZ Technology Holdings Ltd	US$ 13,29 (62,47%)	860,76k
HMRHeidmar Maritime Holdings Corporation	US$ 4,08 (60,00%)	84,65M
ICONIcon Energy Corporation	US$ 0,1356 (45,65%)	85,57M
AVAHAveanna Healthcare Holdings Inc	US$ 5,15 (37,70%)	3,4M
CMCTCreative Media and Community Trust Corporation	US$ 0,35 (-46,15%)	2,1M
SPHLSpringview Holdings Ltd	US$ 0,7194 (-41,98%)	2,7M
ADTXAditxt Inc	US$ 0,0339 (-40,32%)	118,87M
ULYUrgent ly Inc	US$ 0,3086 (-39,44%)	1,76M
PSTVPlus Therapeutics Inc	US$ 0,7501 (-38,01%)	3,89M
SPGCSacks Parente Golf Inc	US$ 0,1388 (28,52%)	365,79M
NVDANVIDIA Corporation	US$ 115,58 (-0,14%)	298,57M
INTCIntel Corporation	US$ 23,70 (14,60%)	243,25M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8,585 (-6,07%)	217,49M
TQQQProShares UltraPro QQQ	US$ 57,79 (-5,46%)	121,22M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biomerica Inc (BMRA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Biomerica Inc

BMRA Dernières nouvelles

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

BMRA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biomerica Inc (BMRA) Cours

Biomerica Inc (BMRA)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Biomerica Inc

BMRA Dernières nouvelles

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

BMRA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités